How to manage antibiotics

The use of PSP/reg biomarkers and body temperature to manage antibiotic therapy addresses the challenge of antibiotic misuse by ensuring timely and appropriate antibiotic administration, reducing unnecessary use and resistance.

JP2024542180AActive Publication Date: 2024-11-13ABIONIC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024528530
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-11-25
Publication Date
2024-11-13
Estimated Expiration
2041-11-25

AI Technical Summary

Technical Problem

The overuse and misuse of antibiotics have led to the rise of antibiotic-resistant bacteria, making it difficult to treat infections, increasing healthcare costs, and prolonging hospital stays, while current methods for identifying bacterial infections are slow and unreliable, often resulting in unnecessary antibiotic administration.

Method used

A method using pancreatic stone protein/regenerating protein (PSP/reg) biomarker levels in conjunction with body temperature to guide the initiation, modification, or discontinuation of antibiotic therapy, providing rapid and accurate guidance for antibiotic administration.

Benefits of technology

Enables timely and appropriate antibiotic use, reducing unnecessary administration, preventing antibiotic resistance, and improving patient outcomes by ensuring early and targeted antibiotic treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542180000001_ABST
    Figure 2024542180000001_ABST
Patent Text Reader

Abstract

The present invention relates to a method for the determination of criteria for whether antibiotic administration to a human or animal subject should be initiated, modified, withheld or discontinued. The method may comprise the steps of determining a first level of pancreatic stone protein / regenerative protein (PSP / reg) in a sample from said human or animal subject and comparing the level of PSP / reg with a predefined threshold. A level of PSP / reg above the predefined threshold is an indication that antibiotic administration should be initiated or modified. A level of PSP / reg below the predefined threshold is an indication that antibiotic administration should be withheld or discontinued.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to methods for managing antibiotic administration, particularly to guide physicians in deciding to initiate or modify an administered antibiotic. [Background technology]

[0002] Antibiotics are medicines used to prevent and treat bacterial infections; they have revolutionized healthcare since the 1930s and have been crucial in saving millions of lives. However, systematic overuse and misuse of antibiotics has led to an alarming increase in the number of antibiotic-resistant bacteria, which are harder to treat and cause more severe and deadly infections. International and national healthcare organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have identified antibiotic resistance as one of the greatest threats to global health in the modern era. Overprescription of antibiotics by healthcare workers is a major contributing factor in the cause of resistance, with a direct relationship between antibiotic consumption and the emergence and dissemination of resistant bacterial strains (Nature. 2013:495(7440):141). Studies have shown that antibiotic therapy is misprescribed to as many as 60% of patients receiving hospital care, and may be even higher outside this environment (Luyt et al., Critical Care, 2014). Aside from contributing to resistance, inappropriate antibiotic use can result in increased mortality and severe illness, increased healthcare costs, longer hospital stays, and the need for more complex treatments that carry a higher risk of unwanted side effects and undesirable drug interactions.

[0003]

[0002] Current antibiotic consumption is on the rise due to an increasing aging population, an increasing frequency of surgical interventions requiring preventive treatment, and an increasing incidence of sepsis (Klein et al., PNAS, 2018). Clinicians use a combination of clinical signs and symptoms to assess whether a patient needs antibiotics. However, the non-specific clinical picture of infection and sepsis makes it difficult to confirm or exclude bacterial infections, and antibiotics are often prescribed at the risk of not having an infection. On an individual scale, this can be life-saving, but on a global scale, it causes significant problems.

[0004]

[0003] Microbial cultures are taken to identify the causative pathogen and ultimately guide the use of appropriate antibiotics, but taking microbial cultures can take anywhere between 1-7 days to produce results and cannot be relied upon for early treatment. Furthermore, the causative pathogen may not be culturable, resulting in no identification. Thus, a major thrust of antibiotic stewardship efforts is the early and rapid identification of patients with sepsis and especially true bacterial infections, and those who would truly benefit from early administration of broad-spectrum empirical treatment. Data from critically ill adults with septic shock indicate an 8% increase in mortality for every hour that the administration of appropriate antibiotics is delayed (Kumar et al., Critical Care Medicine, 2006).

[0005]

[0004] Therefore, there is a high need for novel biomarker-based antibiotic strategies, which is further demonstrated by the marginal value of microbial cultures in patients with sepsis. Namely, in a recent systematic review and meta-analysis of seven studies including a total of 22,655 patients, the proportion of patients with culture-positive sepsis or culture-positive septic shock was only 40.1% (Yuting et al., Critical Care, 2021). This is illustrated by the fact that a significant number of bacterial pathogens are not culturable in laboratory settings, resulting in false-negative identification of bacterial infections.

[0006]

[0005] Furthermore, accurate identification of patients who do not require antibiotics is equally important in safely reducing unnecessary use and allowing physicians to focus on identifying the true underlying cause of disease.

[0007]

[0006] Therefore, it is still paramount to identify early which patients will benefit from immediate antibiotic treatment and which patients do not need immediate antibiotic treatment. Furthermore, since the first-line treatment is typically to administer broad-spectrum antibiotics, it is important to closely monitor the patient's condition and observe if this treatment does not eliminate the bacterial infection (e.g., due to antibiotic resistance) and immediately change the antibiotic regime. The latest Sepsis Save Life Campaign (SSC) guidelines from October 2021 make clear the importance of immediate identification, emphasizing that appropriate antibiotic treatment must be administered within the first hour.

[0008]

[0007] Pancreatic stone protein / regeneration protein (PSP / reg) belongs to a family of lectin-binding proteins that react much earlier during infection, sepsis, septic shock and organ dysfunction than all other current solutions proposed by international guidelines (C S Seager et al., JAMA 2016, 315:8:801-810) or medical societies.

[0009]

[0008] A literature review summarizing 13 PSP / reg studies was published in 2019 (P. Eggimann et al., Biomarkers 2019, 13:02:135-145), and a promising study was published in January 2020 from the Burn center at the University Hospital of Zurich (HJ Klein et al., Ann Surg. 2020).

[0010]

[0009] These numerous publications indicate that the PSP / reg assay is more specific and sensitive than other biomarkers for early diagnosis of sepsis, septic shock and multiple organ failure in ICU adult (M. Llewlyn et al., Crit. Care 2013, 17:2:R60), pediatric (Z. Jiri et al., Cytokine 2014, 66:2:106-111), neonatal (A. Rass et al., BioMed. Res. Int 2016, 1-8) and burn (HJ Klein et al., World Journal of Surgery 2020, 44:3000-3009) patients. PSP / reg allows the identification of sepsis in patients after cardiac surgery (H. Klein et al., PLoS ONE 2015, 10:3:e0120276), PSP / reg predicts outcome in patients with peritonitis in the ICU (R. Gukasjan et al., Crit. Care Med 2013, 41:4:1027-1036), PSP / reg is a biomarker of organ failure in ventilator-associated pneumonia (VAP) (L. Boeck et al., Chest 2011, 140:4:925-932) and predicts mortality in adults (Y.-A. Que et al., Crit. Care 2012, 16:4:R114) and children (Q. Wu et al., Med. Sci. Monit 2017, 23:1533-1539).

[0011]

[0010] The value of PSP / reg was determined in healthy subjects in 2015 (E. Schlapbach et al., BMC Anesthesiol 2015, 15:168). PSP / reg detects early infection and sepsis in trauma patients (M. Keel et al., Crit. Care Med 2009, 37:5:1642-1648), emergency departments (L. Garcia de Guardinia-Romualdo et al., Eur. J. Clin. Invest 2017, 47:4:297-304), acute osteomyelitis in children (C. Cui et al., Med. Sci. Monit 2017, 23:5211-5217), and cancer patients with febrile neutropenia (L. Garcia de Guardiana-Romualdo et al., Clin Chem Lab Med 2019, 57:4:540-548).

[0012]

[0011] Although the pathophysiological mechanism of PSP / reg has not yet been clearly defined (R. Graf, Pancreatology 2020, 20:3:301-304), studies in rats suggest that this serum PSP / reg in septic patients is derived mainly through the acute phase reaction of the pancreas (T. Reding et al., Oncotarget 2017, 8:30162-30174). In humans, PSP / Reg activates granulocyte neutrophils (M. Keel et al., Crit. Care Med 2009, 37:51642-1648), which seems to confirm that PSP / reg can function as an acute phase protein.

[0013]

[0012] In addition to the benefit of PSP as an emerging biomarker of infection and sepsis, it is well established that changes in a patient's temperature play a role in predicting sepsis, but does not have a sufficiently high diagnostic accuracy by itself (Global Sepsis Alliance). Under healthy conditions, temperature can fluctuate approximately + / - 0.5°C each day around an average of 37.0°C, and according to the Sepsis Alliance, abnormal temperatures outside of basal values ​​are a major indicator of infection and sepsis.

[0014]

[0013] Corporal temperature can be assessed in almost any healthcare setting, from primary care to specialist intensive care services.

[0015]

[0014] Unnecessary antibiotic use must be prevented and earlier administration must occur.

[0016]

[0015] Thus, there is a need to provide methods for determining the criteria for whether antibiotic administration to a human or animal subject should be initiated, modified, withheld, or discontinued. Summary of the Invention

[0017]

[0016] The present inventors have developed a new method that uses the determination of biomarker levels of PSP / reg in subject samples to allow rapid, accurate and early guidance of antibiotic administration.

[0018] It has been surprisingly observed that PSP / reg levels above a certain threshold are a strong indication that antibiotic administration is required, or, if antibiotics have already been administered, PSP / reg levels above a certain threshold are a strong indication that alteration of antibiotic administration is required.

[0019] Conversely, it has been surprisingly observed that a PSP / reg level below a predefined threshold is a strong indication that antibiotic administration should be withheld, or, if antibiotics have already been administered, a PSP / reg level below a predefined threshold is a strong indication that antibiotic administration should be discontinued.

[0020]

[0019] An easily identifiable clinical sign: temperature was also used in combination with PSP / Reg biomarkers for rapid, accurate, and early guidance of antibiotic dosing or, if antibiotics were already administered, modification of antibiotic dosing is required.

[0021]

[0020] It is an aspect of the present disclosure to provide a method for determining criteria for whether antibiotic administration to a human or animal subject should be initiated, modified, withheld, or discontinued.

[0022]

[0021] Preferably, the method comprises the step of determining a first level of pancreatic stone protein / regeneration protein (PSP / reg) in a sample from said human subject or said animal subject.

[0023]

[0022] Preferably, the method further comprises the step of comparing the level of PSP / reg with a predetermined threshold.

[0024]

[0023] Preferably, a level of PSP / reg above a certain threshold is an indication that antibiotic administration should be initiated or modified.

[0025]

[0024] Preferably, a level of PSP / reg below a predefined threshold is an indication that antibiotic administration should be withheld or discontinued.

[0026]

[0025] In another aspect of the present disclosure, the method includes determining a second level of PSP / reg in a sample from the human subject or animal subject after a period of time and comparing the second level of PSP / reg with the first level of PSP / reg, wherein an increase in the PSP / reg level between the two measurements is an indication that antibiotic administration should be initiated or modified and a decrease in the PSP / reg level between the two measurements is an indication that antibiotic treatment should be withheld or discontinued.

[0027] According to another aspect of the present disclosure, the period of time is one day.

[0028]

[0027] According to yet another aspect of the present disclosure, the increase in PSP / reg levels is an increase in PSP / reg of at least 50 ng / ml, and the decrease in PSP / reg levels is a decrease in PSP / reg of at least 50 ng / ml.

[0029] According to yet another aspect of the present disclosure, the first level of PSP / reg and / or the second level of PSP / reg are determined in vitro.

[0030] According to another aspect of the present disclosure, the first level of PSP / reg and / or the second level of PSP / reg are determined at the point of care and / or in an analytical laboratory.

[0031]

[0030] According to another aspect of the present disclosure, the first level of PSP / reg and / or the second level of PSP / reg are determined by at least one from the list including ELISA, RIA, EIA, mass spectrometry, microarray analysis and fluidic assay.

[0032] According to yet another aspect of the present disclosure, the predetermined threshold is PSP / reg 200 ng / ml.

[0033] In yet another embodiment, a level of PSP / reg below 200 ng / ml indicates a low probability of bacterial infection.

[0034]

[0033] According to another aspect of the present disclosure, a level of PSP / reg greater than 200 ng / ml indicates a high likelihood of developing a bacterial infection.

[0035]

[0034] According to yet another aspect of the present disclosure, the method further includes a step of determining the body temperature of the human or animal subject, wherein an increase in body temperature outside the basal range is an indication that antibiotic administration should be initiated.

[0036]

[0035] In yet another embodiment, the basal ranges include between 97F (36.5°C) and 99F (37.5°C) for adults and between 97.9F (36.6°C) and 100.4F (38.0°C) for infants and children.

[0037]

[0036] According to another aspect of the present disclosure, the sample includes at least one from the list including whole blood, serum, plasma, urine, sputum, cerebrospinal fluid, tears, saliva, sweat, breast milk, extracts from solid tissue and extracts from fecal material.

[0038] The present invention relates to a method for managing the initiation of antibiotic therapy in a patient, whereby the level of pancreatic stone protein / regenerative protein (PSP / reg) is determined in a body fluid sample.

[0039]

[0038] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate presently preferred embodiments of the invention and, together with the general description given above and the detailed description given below, serve to explain features of the invention. [Brief description of the drawings]

[0040] [Figure 1A]Graph showing patient case report. The patient was admitted to the ICU with severe COVID-19 pneumonia and was placed on invasive mechanical ventilation from day 1. The patient received empirical antibiotics during the first 2 days as per hospital protocol. PSP / Reg was routinely monitored by observation. On day 3, microbiological broncho aspirate sampling was performed and no pathogens were detected. However, the patient received unnecessary antibiotics during the first 2 days. PSP / Reg suddenly increased by 112% between days 5 and 6, and the patient was observed to have a fever on day 6. Microbiological cultures were then taken on days 7 and 8 (bronchial aspirate and broncho lavage, respectively) and the results obtained on day 9 confirmed the presence of the pathogen, prompting the initiation of antibiotic treatment on day 9. [Figure 1B] 1 is a graph showing a similar case report when the method according to the present disclosure is applied. Low PSP / Reg concentrations during the first 5 days allow for the withholding of unnecessary antibiotics. A sudden 112% increase in PSP / Reg between days 5 and 6, together with the presence of an abnormal temperature of 38.6°C, triggers the early and now appropriate administration of antibiotics. A decrease in PSP / Reg concentrations below 200ng / ml after the initiation of antibiotics, as seen on day 9, indicates that unnecessary antibiotics can be discontinued. [Diagram 2] FIG. 1 is a table showing the management of antibiotic administration according to PSP / reg concentration and / or temperature. [Figure 3A] Figure 1 shows a box plot of the 5th and 95th percentiles and the mean median PSP concentrations shown as crosses. Data points are from adult patients admitted to the intensive care unit, grouped by the number of days they received or did not receive antibiotics. The Mann-Whitney test shows a statistically significant difference between the group of patients who did not require antibiotics (mean 89 ng / ml) and the group of patients who did require antibiotics (mean 286 ng / ml) with a P value of 0.0002 (***). [Figure 3B]Figure 1 shows box plots of the 5th and 95th percentiles and the mean median PSP concentrations shown as crosses. Applying a cutoff of 200 ng / ml PSP / reg to the data points, the number of patients receiving unnecessary antibiotics can be reduced from 17 to 9. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0041]

[0044] The present invention relates to methods for the determination of criteria for whether antibiotic administration to a human or animal subject should be initiated, modified, withheld, or discontinued.

[0042]

[0045] The method may comprise determining a first level of pancreatic stone protein / regeneration protein (PSP / reg) in a sample from said human subject or said animal subject.

[0043]

[0046] The method may further comprise the step of comparing the level of PSP / reg to a predetermined threshold.

[0044]

[0047] Levels of PSP / reg above a certain threshold are an indication that antibiotic administration should be initiated or modified.

[0045]

[0048] A level of PSP / reg below a certain threshold is an indication that antibiotic administration should be withheld or discontinued.

[0046]

[0049] Antibiotic administration may be withheld until the level of PSP / reg reaches a predetermined threshold, which indicates that antibiotic administration should be initiated or resumed.

[0047]

[0050] Altering antibiotic administration may include altering the type of antibiotic administered to the subject or altering the antibiotic administration regimen.

[0048]

[0051] The antibiotic may be selected from the list comprising at least one of penicillins, tetracyclines, cephalosporins, quinolones, lincomycins, macrolides, sulfonamides and glycopeptides.

[0049]

[0052] The method may further comprise determining a second level of PSP / reg in said human subject or said animal subject's sample after a period of time.

[0050]

[0053] The second level of PSP / reg may be compared to the first level of PSP / reg.

[0051]

[0054] An increase in PSP / reg levels between the two measurements is an indication that antibiotic administration should be initiated or altered.

[0052]

[0055] A decrease in PSP / reg levels between the two measurements is an indication that antibiotic treatment should be withheld or discontinued.

[0053]

[0056] The first level of PSP / reg and / or the second level of PSP / reg are determined in vitro, for example in an analytical laboratory or facility. A human or animal subject may not be present or required during the determination of the first level of PSP / reg and / or the second level of PSP / reg.

[0054]

[0057] The period of time may be one day or 24 hours.

[0055]

[0058] Alternatively, the period of time may be less than a day, for example 6 hours, 12 hours or 18 hours, or any suitable period of time.

[0056]

[0059] The increase in PSP / reg levels between the two measurements may be an increase of at least 50%.

[0057]

[0060] The increase in PSP / reg levels between the two measurements may be an increase of at least 50 ng / ml of PSP / reg.

[0058]

[0061] The decrease in PSP / reg levels between the two measurements may be at least a 50% decrease.

[0059]

[0062] The decrease in PSP / reg levels between the two measurements may be at least a 50 ng / ml decrease in PSP / reg.

[0060]

[0063] The predetermined threshold may be substantially 200ng / ml PSP / reg.

[0061]

[0064] The predetermined threshold may be PSP / reg 150ng / ml to 250ng / ml, or 160ng / ml to 240ng / ml, or 170ng / ml to 230ng / ml, or PSP / reg 180ng / ml to 220ng / ml, or PSP / reg 190ng / ml to 210ng / ml.

[0062]

[0065] The predetermined threshold may be substantially 150ng / ml PSP / reg.

[0063]

[0066] The predetermined threshold may be substantially 250ng / ml PSP / reg.

[0064]

[0067] For example, a threshold of 150 ng / ml PSP / reg may be used for human subjects not in an intensive care unit but suspected of being infected.

[0065]

[0068] Alternatively, a threshold of 200 ng / ml PSP / reg may be used for human subjects in intensive care units who are not suspected of infection.

[0066]

[0069] A threshold of 250 ng / ml PSP / reg may be used for human subjects in intensive care units suspected of infection.

[0067]

[0070] Levels of PSP / reg above a given threshold indicate a high likelihood of developing a bacterial infection.

[0068]

[0071] A level of PSP / reg below a given threshold indicates a low likelihood of developing a bacterial infection.

[0069]

[0072] Levels of PSP / reg above a given threshold indicate a high likelihood of developing a bacterial infection.

[0070]

[0073] The methods of the present disclosure may further comprise the step of determining the body temperature of the human or animal subject.

[0071]

[0074] An elevation of temperature outside the basal range may be an indication or a secondary indication that antibiotics should be initiated.

[0072]

[0075] The basal range of human subject body temperatures may be included between 97F (36.5°C) and 99F (37.5°C) for adults, and between 97.9F (36.6°C) and 100.4F (38.0°C) for infants and children.

[0073]

[0076] For animal subjects, the basal ranges may fall within the same ranges as the basal ranges for human subjects or within ranges specific to the species of the animal subject.

[0074]

[0077] The sample may comprise at least one from the list including whole blood, serum, plasma, urine, sputum, cerebrospinal fluid, tears, saliva, sweat, breast milk, extracts from solid tissue and extracts from fecal material.

[0075]

[0078] On the one hand, the present disclosure aids in the decision to administer appropriate antibiotics early and in a timely manner, and on the other hand, the present disclosure avoids the routine administration of antibiotics to patients who do not require treatment and guides medical personnel in the decision to discontinue antibiotic therapy.

[0076]

[0079] By very careful monitoring of PSP / reg levels it becomes possible to adapt the regime or administer the antibiotic of choice.

[0077]

[0080] "PSP / reg" as defined herein refers to human pancreatic stone protein, also called regeneration gene (REG) I protein or lithostatin or pancreatic thread protein (Gross et al., J. Clin. Invest. 1985, 76:21 15-2126), which can be isoform alpha (Uniprot SEQ ID NO: P05451, also identified herein as SEQ ID NO: 1) or isoform beta (Uniprot SEQ ID NO: P48304, also identified herein as SEQ ID NO: 2).

[0078]

[0081] Body fluids that are useful for determining PSP / reg levels are, for example, whole blood, serum, plasma, urine, sputum, cerebrospinal fluid, tears, saliva, sweat, breast milk, or extracts from solid tissues or from fecal material.

[0079]

[0082] For the determination of the level of PSP / reg in body fluids, any known method can be used, such as, for example, ELISA, RIA, EIA, mass spectrometry or microarray analysis and any fluid assay method.

[0080]

[0083] FIG. 1A shows the evolution over 10 days of the levels of PSP measured in whole blood of a patient admitted to the ICU with severe COVID-19 pneumonia. The patient was placed under invasive mechanical ventilation from day 1 and received antibiotics for the first 2 days. On day 3, unnecessary antibiotic therapy for the first 2 days was confirmed by a negative microbiological bronchial aspirate sampling. Between days 5 and 6, PSP increased by 112% and on day 6, the patient was found to have a fever. On day 9, a bacterial infection was confirmed by a subsequent positive microbiological bronchial aspirate sampling and antibiotic therapy was started. The presented patient case report clearly shows how PSP-based antibiotic therapy could benefit the patient in preventing unnecessary administration of antibiotics as well as in earlier administration of antibiotics at the onset of infection. Indeed, if the level of PSP is lower than a certain threshold, antibiotic administration can be withheld and inappropriate antibiotic use, which is responsible for an increase in complications and undesirable side effects, can be prevented.

[0081]

[0084] An increase in the levels of PSP combined with a temperature outside the normal range may also be an indication to begin administering earlier antibiotic therapy starting on day 6 instead of day 9 when microbiology results become available.

[0082]

[0085] FIG. 1B shows a patient journey similar to FIG. 1A, but with the application of the herein presented method of antibiotic management based on the measurement of PSP and temperature levels. Low levels of PSP during the first 5 days allow to refrain from unnecessary antibiotic treatment, reducing complications, the risk of undesirable side effects, the need for more complicated treatment, as well as the development of antibiotic resistance. A sudden 112% increase in PSP levels between days 5 and 6, in conjunction with the presence of an abnormal temperature, may be a triggering sign for the now appropriate administration of antibiotics. This timely administration of antibiotic treatment may help to increase better treatment outcomes and reduce hospitalization. A decrease in PSP levels to low levels after the initiation of antibiotics, as seen on day 9, indicates a stage where de-escalation of antibiotic treatment can be performed.

[0083]

[0086] Based on the patient case described in Figure 1, a decision table for PSP-based management of antibiotic therapy was established and is shown in Figure 2. A measured level of PSP lower than 200 ng / ml or a PSP level that has decreased by 50% between two subsequent measurements indicates to the medical personnel to either discontinue or withhold unnecessary antibiotic treatment. In association with a temperature outside the normal range, a PSP level above 200 ng / ml or a 50% increase between two subsequent measurements may be an indication to either continue or modify an already started antibiotic treatment or to start antibiotic treatment.

[0084]

[0087] Figure 3 further highlights the effectiveness of the PSP-based antibiotic stewardship approach for initiating or withholding antibiotic therapy in patients with suspected bacterial infection. Observational PSP / Reg measurements from adult patients undergoing ICU treatment were summarized by whether the patient received antibiotics or not (see Figure 3A). After applying a cutoff of PSP / Reg 200 ng / ml, we naturally and surprisingly observed that the number of patients who would require antibiotic treatment decreased from 17 to 9 (see Figure 3B).

[0085]

[0088] The present invention makes it possible to prevent unnecessary antibiotic use and indicate when earlier doses of antibiotics should be administered, potentially resulting in reduced risk of antibiotic resistance and better patient treatment outcomes.

[0086]

[0089] Although the present invention has been disclosed with reference to certain preferred embodiments, numerous modifications, variations, and alterations to the described embodiments, and equivalents thereof, are possible without departing from the field and scope of the present invention. It is therefore intended that the present invention not be limited to the described embodiments, but rather be accorded the broadest reasonable interpretation in accordance with the language of the appended claims.

Claims

1. 1. A method for determining criteria for initiating, modifying, withholding, or ceasing antibiotic administration to a human or animal subject, comprising: determining a first level of pancreatic stone protein / regeneration protein (PSP / reg) in a sample from said human subject or said animal subject; comparing the level of PSP / reg to a predetermined threshold; Including, a level of PSP / reg above said predetermined threshold is an indication that antibiotic administration should be initiated or modified; A method, wherein a level of PSP / reg below said predetermined threshold is an indication that antibiotic administration should be withheld or discontinued.

2. determining a second level of PSP / reg in the human or animal subject sample after a period of time and comparing said second level of PSP / reg with said first level of PSP / reg; An increase in PSP / reg levels between the two measurements is an indication that antibiotic administration should be initiated or modified; 2. The method of claim 1, wherein a decrease in the PSP / reg level between the two measurements is an indication that antibiotic treatment should be withheld or discontinued.

3. The method of claim 2 , wherein the period of time is one day.

4. 4. The method of claim 2 or 3, wherein said increase in PSP / reg levels is an increase in PSP / reg of at least 50 ng / ml and said decrease in PSP / reg levels is a decrease in PSP / reg of at least 50 ng / ml.

5. The method according to any one of claims 1 to 4, wherein the first level of PSP / reg and / or the second level of PSP / reg are determined in vitro.

6. 6. The method of claim 5, wherein the first level of PSP / reg and / or the second level of PSP / reg are determined at a point of care or in an analytical laboratory.

7. The method of claim 5 or 6, wherein the first level of PSP / reg and / or the second level of PSP / reg are determined by at least one from the list including ELISA, RIA, EIA, mass spectrometry, microarray analysis and fluid assay.

8. The method according to any one of claims 1 to 7, wherein said predetermined threshold is comprised between PSP / reg 150 ng / ml and PSP / reg 250 ng / ml.

9. The method according to any one of claims 1 to 8, wherein the predetermined threshold is PSP / reg 200 ng / ml.

10. 10. The method of claim 9, wherein a level of PSP / reg below 200 ng / ml indicates a low likelihood of developing a bacterial infection.

11. 10. The method of claim 9, wherein a level of PSP / reg above 200 ng / ml indicates an increased likelihood of developing a bacterial infection.

12. determining a body temperature of the human or animal subject; The method according to any one of claims 1 to 11, wherein said increase in body temperature outside the basal range is an indication that antibiotic administration should be initiated.

13. 13. The method of claim 12, wherein the basal range is comprised between 97F (36.5°C) and 99F (37.5°C) for adults and between 97.9F (36.6°C) and 100.4F (38.0°C) for infants and children.

14. 14. The method according to any one of claims 1 to 13, wherein the sample comprises at least one from the list comprising whole blood, serum, plasma, urine, sputum, cerebrospinal fluid, tears, saliva, sweat, breast milk, extracts from solid tissue and extracts from fecal material.

Citation Information

Patent Citations

  • Method for assaying sepsis in humans

    CN101796418A

  • Methods for measuring human sepsis

    JP2010538282A

  • Method for assaying lower respiratory tract infection or inflammation

    US20130079296A1